NCT05087342CompletedPhase 3
Latino Semaglutide Study
A Randomized Latino Semaglutide 2.4mg Study
Source: ClinicalTrials.gov · Last updated 15 Oct 2024
Brief summary (registry, in English)
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 119 (actual)
- First submitted
- 20 Sept 2021
- Start date
- 13 Dec 2022
- Primary completion date
- 29 May 2024
- Lead sponsor
- Loma Linda University
- Diseases
- Obesity
- NCT number
- NCT05087342
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 119
- From 13 Dec 2022 to the primary completion date, 29 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medication use targeting the GPL-1 system
- In the last 30 days, attempted to lose weight by lifestyle modification alone or with the use of anti-obesity medications resulting in more than 5 pounds of weight loss.
- Use of obesogenic medications (including but not limited to steroids, haloperidol, clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and lithium) which cannot be substituted or stopped.
- Previous participation in this trial, either initial screening or group randomization
Other illness
- Current cancer treatment
- Diabetes, Type 1 or Type 2
- Eating disorders
- History of bariatric surgery
- Genetic disorders and/or physical or mental handicaps that would limit participation in the study and/or the intensive lifestyle intervention.
- Any contraindication to semaglutide 2.4 mg including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2, hypersensitivity to semaglutide 2.4 mg or any product components.
- Any known or suspected allergy to semaglutide 2.4 mg or related products
Other
- Pregnant or planning to become pregnant in the next 8 months
Who the study is looking for
- Self-identify as being of Hispanic/Latino ethnicity
- BMI \>30
- Age 18-75 years old
- Able to provide informed consent before any trial related activities
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Loma Linda University Health Coordinator of this site? Confirm its status | Loma Linda | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.